Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus +TM veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; HeskaView, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Additionally, the company provides a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. It sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is based in Loveland, Colorado.
IPO Year: 1997
Exchange: NASDAQ
Website: heska.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2023 | $58.00 | Equal-Weight → Underweight | Morgan Stanley |
| 3/1/2022 | $190.00 → $161.00 | Equal-Weight | Morgan Stanley |
| 2/23/2022 | $300.00 → $250.00 | Overweight | JP Morgan |
| 1/6/2022 | $210.00 | Overweight | Piper Sandler |
| 11/18/2021 | $190.00 | Equal-Weight | Morgan Stanley |
| 8/4/2021 | $240.00 → $305.00 | Overweight | Piper Sandler |
| 7/12/2021 | $280.00 | Neutral → Buy | Guggenheim |
4 - HESKA CORP (0001038133) (Issuer)
4 - HESKA CORP (0001038133) (Issuer)
4 - HESKA CORP (0001038133) (Issuer)
4 - HESKA CORP (0001038133) (Issuer)
4 - HESKA CORP (0001038133) (Issuer)
4 - HESKA CORP (0001038133) (Issuer)
4 - HESKA CORP (0001038133) (Issuer)
4 - HESKA CORP (0001038133) (Issuer)
4 - HESKA CORP (0001038133) (Issuer)
4 - HESKA CORP (0001038133) (Issuer)
LOVELAND, Colo., Jan. 12, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or "Company"), a leading global provider of advanced veterinary diagnostic and specialty products, appointed Dr. Joachim Hasenmaier, the former head of Boehringer Ingelheim Animal Health, to the Company's Board of Directors, effective January 11, 2021. Dr. Joachim Hasenmaier most recently served as a member of the board of managing directors of Boehringer Ingelheim, a world-leading, research-driven pharmaceutical company, where he oversaw the animal health and consumer healthcare businesses. Previously, as head of animal health of Boehringer Ingelheim, Dr. Hasenmaier led the rapid growth and expansion
eXp World Holdings, Inc. (NASDAQ:EXPI) shares are trading higher on Thursday after S&P Dow Jones Indices stated that the company will replace Heska Corporation (NASDAQ:HSKA) in the S&P Smallcap 600. What To Know: eXp World Holdings will join the S&P SmallCap 600 effective prior to the opening of trading on June 14. eXp World Holdings will replace Heska Corp. which is being acquired by Mars Inc. in a deal that is expected to be completed soon. eXp World Holdings is the holding company for eXp Realty, LLC which owns and operates a portfolio of service-based businesses. Its Virbela segment includes Virbela enterprise metaverse technology and support services. Related News: Why Carvana Sha
Benzinga Pro data, Heska (NASDAQ:HSKA) reported Q1 sales of $62.38 million. Earnings fell to a loss of $10.12 million, resulting in a 139.87% decrease from last quarter. In Q4, Heska brought in $66.34 million in sales but lost $4.22 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Heska posted an ROCE of -0.02%. It is important
Heska (NASDAQ:HSKA) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $(0.50) by 134 percent. This is a 37.04 percent decrease over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $62.38 million which missed the analyst consensus estimate of $64.37 million by 3.09 percent. This is a 3.73 percent decrease over sales of $64.80 million the same period last year.
Heska (NASDAQ:HSKA) reported its Q1 earnings results on Friday, May 5, 2023 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Heska beat estimated earnings by 134.0%, reporting an EPS of $0.17 versus an estimate of $-0.5. Revenue was down $2.42 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.59 which was followed by a 4.74% increase in the share price the next day. Here's a look at Heska's past performance: Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022 EPS Estimate -0.04 -0.11 -0.03 EPS Actual 0.55 0.41 0.34 0.27 Revenue Estimate 64.66M 68.10M 68.58M 65.92M Revenue Actual 66.34M 61.49M 64.68M
Heska (NASDAQ:HSKA) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $(0.41) by 141.46 percent. This is a 37.04 percent decrease over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $62.38 million which missed the analyst consensus estimate of $64.25 million by 2.91 percent. This is a 3.73 percent decrease over sales of $64.80 million the same period last year.
Morgan Stanley analyst Erin Wilson maintains Heska (NASDAQ:HSKA) with a Equal-Weight and raises the price target from $58 to $120.
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dropping around 80 points on Monday. The Dow traded up 0.89% to 33,571.43 while the NASDAQ fell 0.66% to 12,142.07. The S&P 500, also rose, gaining, 0.17% to 4,116.15. Check This Out: Top 4 Materials Stocks That Set To Fly In April Leading and Lagging Sectors Energy shares jumped by 4.7% on Friday. Meanwhile, top gainers in the sector included Nine Energy Service, Inc. (NYSE:NINE), up 15%, and BP Prudhoe Bay Royalty Trust (NYSE:BPT), up 19%. In trading on Friday, consumer discretionary fell by 1.4%. Top Headline The ISM manufacturing PMI fell to 46.3 in March versus a reading of 47.7 in February, mis
Gainers Cano Health (NYSE:CANO) shares increased by 46.1% to $1.33 during Monday's regular session. Trading volume for this security as of 13:30 EST is 27.8 million, which is 333.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $351.3 million. Pulse Biosciences (NASDAQ:PLSE) stock rose 25.0% to $4.2. Trading volume for this security as of 13:30 EST is 369.8K, which is 666.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $156.3 million. As per the press release, Q4 earnings came out 2 days ago. Passage Bio (NASDAQ:PASG) stock increased by 23.73% to $1.19. Trading volume f
Gainers Nogin, Inc. (NASDAQ:NOGN) shares surged 172.4% to $7.41. Guardforce AI Co., Limited (NASDAQ:GFAI) jumped 101% to $14.24 after climbing 50% on Friday. Harbor Custom Development, Inc. (NASDAQ:HCDI) surged 48% to $6.42. On Friday, Harbor Custom Development reported worse-than-expected Q4 sales results. U.S. Energy Corp. (NYSE:USEG) gained 31.3% to $2.31. Cano Health, Inc. (NYSE:CANO) rose 30% to $1.1850. Barry Sternlicht, on April 2, entered into group agreement with Elliot Cooperstone, Lewis Gold, Agreed to act together to pursue change at Cano Health. Mangoceuticals, Inc. (NASDAQ:MGRX) gained 26% to $1.4421. Brera Holdings PLC (NASDAQ:BREA) jumped 26% to $3.9711. Barnwell In
15-12G - HESKA CORP (0001038133) (Filer)
EFFECT - HESKA CORP (0001038133) (Filer)
EFFECT - HESKA CORP (0001038133) (Filer)
S-8 POS - HESKA CORP (0001038133) (Filer)
S-8 POS - HESKA CORP (0001038133) (Filer)
S-8 POS - HESKA CORP (0001038133) (Filer)
S-8 POS - HESKA CORP (0001038133) (Filer)
S-8 POS - HESKA CORP (0001038133) (Filer)
S-8 POS - HESKA CORP (0001038133) (Filer)
S-8 POS - HESKA CORP (0001038133) (Filer)
Key Points: $4.5 million in Series Seed 3 funding, led by Prime Movers Lab with participation from At One Ventures, bringing the company's total funding to $10 million. The funding will accelerate Dalan's product pipeline and facilitate its global expansion, aiming to protect the health of honeybees and secure the global food supply. Dalan Animal Health, Inc. ("Dalan"), a pioneering biotech company in insect health, today announced the successful closure of a $4.5 million Series Seed 3 funding round. The round was led by Prime Movers Lab with participation from At One Ventures, bringing Dalan's total funding to $10 million. The additional funding will enable Dalan to expedite its
NEW YORK, June 7, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, June 14: eXp World Holdings Inc. (NASD: EXPI) will replace Heska Corp. (NASD: HSKA). Mars Inc. is acquiring Heska in a deal expected to be completed soon pending final conditions.Privia Health Group Inc. (NASD: PRVA) will replace Ruth's Hospitality Group Inc. (NASD: RUTH). S&P 500 constituent Darden Restaurants Inc. (NYSE:DRI) is acquiring Ruth's Hospitality Group in a deal expected to be completed soon pending final conditions.Following is a summary of the changes that will take place prior to the open of trading on the
Dalan Animal Health, Inc. ("Dalan"), the biotech company pioneering insect health with the world's first honey bee vaccine, is proud to announce its first product shipment to a commercial beekeeper. The shipment is for Trevor Tauzer of Tauzer Apiaries in California and contains 500 doses, potentially protecting 25 million bees at an average of 50,000 bees per hive. This milestone follows the U.S. Department of Agriculture (USDA) granting a conditional license to Dalan's first-in-class honeybee vaccine earlier this year. The vaccine is indicated to protect honeybees against the devastating American Foulbrood disease caused by the bacteria Paenibacillus larvae. Honeybees are a critical co
LOVELAND, Colo., May 5, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty products, reported financial results for its first quarter ended March 31, 2023. First Quarter 2023 and Year Over Year ("YOY") Metrics $ in millions except Earnings Per Share ("EPS") Q1 ($) Q1 (%) YOY Consolidated revenue $62.4 (3.7) % Q1 (%) Q1 YOY bps1 Consolidated gross margin 43.9 % (110) Net loss margin2 (15.7) % (90) Adjusted EBITDA margin3 5.2 % (670) Q1 ($) Q1 (%) YOY Net loss attributable
LOVELAND, Colo., April 21, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, announces its 2023 Annual Meeting of Stockholders. The virtual event is scheduled for 9 a.m. MT / 11 a.m. ET on Wednesday, May 3, 2023. Stockholders of record as of March 6, 2023, are entitled to notice of, participate in and vote at, the annual meeting. All stockholders are encouraged to vote on the proposed matters before the Annual Meeting by proxy as described in the Company's proxy materials provided to stockholders.
The combination of highly complementary businesses and teams will broaden access to diagnostics and technology, accelerate R&D and innovation, and better serve more veterinary professionals and pets. MCLEAN, Va. and LOVELAND, Colo., April 3, 2023 /PRNewswire/ -- Mars, Incorporated ("Mars"), and Heska Corporation (NASDAQ:HSKA) ("Heska") today announced that they have entered into a definitive agreement under which Mars will acquire Heska, a global provider of advanced veterinary diagnostic and specialty products for $120.00 per share. The transaction price represents a premium of approximately 38% over Heska's 60-calendar day volume weighted average price and a premium of approximately 23% ov
Full Year Sales $257.3 Million, Full Year Gross Margin Up 150 Basis Points to 43.2% Full Year North America Lab Consumables Sales Up 8.7%, Total Active Subscriptions Up 18% LOVELAND, Colo., Feb. 28, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty products, reported financial results in two segments (North America and International) for its fourth quarter and full year ended December 31, 2022. Fourth Quarter and Full Year 2022 and Year Over Year ("YOY") Metrics $ in mi
LOVELAND, Colo., Feb. 23, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, announced that members of Heska's management team will present at three institutional investor conferences in March 2023. Bank of America Securities 2023 Animal Health Summit, March 2. Kevin Wilson, Chief Executive Officer and President, will participate in a virtual fireside discussion at 1:20 p.m. ET. Raymond James Virtual 44th Annual Institutional Investors Conference, March
HENDERSON, Nev., Feb. 16, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces its Nu.Q® Vet Cancer Test is now available for pre-order to veterinarians at the point-of-care through Heska Corporation (NASDAQ:HSKA) ("Heska"). The Nu.Q® test will be showcased this weekend in Las Vegas at the 2023 Western Veterinary Conference, one of the world's largest veterinary conferences. Heska's Nu.Q® Canine Cancer Screen and Monitor Test will operate on Heska's proprietary Element i+® Immunodiagnostic Analyzer, a point-of-care platform which provides veterinarians with rapid, accurate, low cost, and easy-to-use on
LOVELAND, Colo., Feb. 8, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its fourth quarter and full year 2022 financial performance in a press release before the market opens on Tuesday, February 28, 2023. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results. To access the conference call: From within the United States, please dial 1-877-41-6152From outside of the United States, please dial 1-201-389-
SC 13G/A - HESKA CORP (0001038133) (Subject)
SC 13G/A - HESKA CORP (0001038133) (Subject)
SC 13G/A - HESKA CORP (0001038133) (Subject)
SC 13G/A - HESKA CORP (0001038133) (Subject)
SC 13G/A - HESKA CORP (0001038133) (Subject)
SC 13G - HESKA CORP (0001038133) (Subject)
SC 13G/A - HESKA CORP (0001038133) (Subject)
SC 13G - HESKA CORP (0001038133) (Subject)
SC 13G/A - HESKA CORP (0001038133) (Subject)
Morgan Stanley downgraded Heska Corp from Equal-Weight to Underweight and set a new price target of $58.00
Morgan Stanley reiterated coverage of Heska with a rating of Equal-Weight and set a new price target of $161.00 from $190.00 previously
JP Morgan reiterated coverage of Heska with a rating of Overweight and set a new price target of $250.00 from $300.00 previously
Piper Sandler resumed coverage of Heska Corp with a rating of Overweight and set a new price target of $210.00
Morgan Stanley initiated coverage of Heska with a rating of Equal-Weight and set a new price target of $190.00
Piper Sandler reiterated coverage of Heska with a rating of Overweight and set a new price target of $305.00 from $240.00 previously
Guggenheim upgraded Heska from Neutral to Buy and set a new price target of $280.00
Raymond James reiterated coverage of Heska with a rating of Outperform and set a new price target of $225.00 from $145.00 previously
Piper Sandler reiterated coverage of Heska with a rating of Overweight and set a new price target of $220.00 from $157.00 previously
Raymond James reiterated coverage of Heska with a rating of Outperform and set a new price target of $225.00 from $145.00 previously
Full Year Sales $257.3 Million, Full Year Gross Margin Up 150 Basis Points to 43.2% Full Year North America Lab Consumables Sales Up 8.7%, Total Active Subscriptions Up 18% LOVELAND, Colo., Feb. 28, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty products, reported financial results in two segments (North America and International) for its fourth quarter and full year ended December 31, 2022. Fourth Quarter and Full Year 2022 and Year Over Year ("YOY") Metrics $ in mi
LOVELAND, Colo., Feb. 8, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its fourth quarter and full year 2022 financial performance in a press release before the market opens on Tuesday, February 28, 2023. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results. To access the conference call: From within the United States, please dial 1-877-41-6152From outside of the United States, please dial 1-201-389-
LOVELAND, Colo., Jan. 3, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty products and solutions, today announced the completion of acquisition of 100% of the shares of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics ("LightDeck"), a pioneer in planar waveguide fluorescence immunoassay diagnostics with strong manufacturing capabilities and research and development expertise (the "Acquisition"). The Acquisition, which was first announced on September 12, 2022, represent
North America Point of Care Lab Consumables up 11.4%, Consolidated Gross Margin up 180 bps LOVELAND, Colo., Nov. 8, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, reported financial results in two segments (North America and International) for its third quarter ended September 30, 2022. In this release, Point of Care is "POC", Pharmaceuticals, Vaccines and Diagnostics is "PVD", Other Vaccines and Pharmaceuticals is "OVP", and basis points is "bps". Thi
LOVELAND, Colo., Oct. 18, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its third quarter 2022 financial performance in a press release before the market opens on Tuesday, November 8, 2022. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results. To access the conference call: From within the United States, please dial 1-800-239-9838From outside of the United States, please dial 1-323-794-2551Reference
LOVELAND, Colo., Sept. 12, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, announced today that the Company has entered a definitive agreement to acquire 100% of the share capital of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics ("LightDeck"), a pioneer in innovative planar waveguide fluorescence immunoassay diagnostics with strong manufacturing and specialized production capabilities (the "Acquisition"). Founded in 2009 and headquartered in Boul
LOVELAND, Colo., Aug. 8, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, reported financial results in two segments (North America and International) for its second quarter ended June 30, 2022. In this release, Point of Care is "POC", Pharmaceuticals, Vaccines and Diagnostics is "PVD", Other Vaccines and Pharmaceuticals is "OVP", and basis points is "bps". Second Quarter 2022 and Year Over Year ("YOY") Metrics $ in millions except Earnings Per Share (
LOVELAND, Colo., July 20, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its second quarter 2022 financial performance in a press release before the market opens on Monday, August 8, 2022. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results. To access the conference call: From within the United States, please dial 1-800-289-0720 From outside of the United States, please dial 1-323-701-0160 R
Quarterly Revenue Up 7% (10% in Constant Currency), Gross Margin Up 290 bps North America POC Lab Consumables Up 10%, Full Year Outlook Reiterated LOVELAND, Colo., May 9, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, reported financial results in two segments (North America and International) for its first quarter ended March 31, 2022. First Quarter 2022 and Year Over Year ("YOY") Metrics $ in millions except Earnings Per Share ("EPS") Q1 ($) Q1 (%) Y
LOVELAND, Colo., April 18, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its first quarter 2022 financial performance in a press release before the market opens on Monday, May 9, 2022. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results. To access the conference call: From within the United States, please dial 1-800-239-9838 From outside of the United States, please dial 1-323-794-2551 Refe